A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

What this study is about

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

Who can join (things the study team will check)

✅ You may be able to join if…

• Participants must have histologically confirmed Stage IV or recurrent Non-small Cell Lung Cancer (NSCLC) of non-squamous (NSQ) histology with no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease.
• Participants must have measurable PD-L1 ≥ 1% Tumor Cell (TC) score by the investigational PD-L1 immunohistochemistry (IHC) assay VENTANA PD-L1 (SP263) CDx Assay conducted by central laboratory during the screening period prior to randomization.
• Participants must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1 criteria.
• Participants must have an Easter Cooperative Oncology Group (ECOG) performance status of ≤ 1 at screening.
• Participants must have a life expectancy of at least 3 months at the time of randomization.

🚫 You may not be able to join if…

• Participants must not be pregnant and/or breastfeeding.
• Participants with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS-1 mutations that are sensitive to available targeted inhibitor therapy. Participants with unknown EGFR, ALK, or ROS-1 status are excluded.
• Participants with known BRAFV600E mutations, that are sensitive to available targeted inhibitor therapy; participants with known activating rearranged during transfection (RET) mutations or neurotrophic tyrosine receptor kinase (NTRK) fusion gene alterations are excluded. Participants with unknown or indeterminate BRAF mutation, activating RET mutations or NTRK fusion gene alterations are eligible.
• Participants must not have untreated central nervous system (CNS) metastases.
• Participants must not have leptomeningeal metastases (carcinomatous meningitis).
• Participants must not have concurrent malignancy requiring treatment.
• Participants must not have an active autoimmune disease.
• Participants must not have history of interstitial lung disease or pneumonitis that required oral or intravenous (IV) glucocorticoids to assist with management.
• Participants must not have a history of myocarditis.
• Participants must not have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or other antibody or drug targeting T-cell co-stimulation or checkpoint pathways.
• Other protocol-defined Inclusion/Exclusion criteria apply.

Where this trial is running

• Local Institution - 0487, Mobile, Alabama, United States
• Southern Arizona VA Health Care System, Tucson, Arizona, United States
• Local Institution - 0112, Los Angeles, California, United States
• University of California Davis (UC Davis) Comprehensive Cancer Center, Sacramento, California, United States
• San Francisco Oncology Associates, San Francisco, California, United States
• UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
• Local Institution - 0500, Grand Junction, Colorado, United States
• Local Institution - 0472, Westminster, Colorado, United States
• University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami, Florida, United States
• Memorial Hospital West, Pembroke Pines, Florida, United States
• Florida Cancer Specialists - North, St. Petersburg, Florida, United States
• Local Institution - 0477, Tamarac, Florida, United States

+ 308 more sites.

Who to contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06561386.